8-KOther Events

JOHNSON & JOHNSON 8-K Report, Corporate Update (May 7, 2007)

Filed May 7, 2007For Securities:JNJ

Summary

Johnson & Johnson (JNJ) has filed an 8-K report on May 7, 2007, to announce an update regarding the COSTAR II clinical trial. This pivotal study is evaluating the CoStarr cobalt chromium paclitaxel-eluting coronary stent, developed by its wholly-owned subsidiary, Conor Medsystems, LLC. The press release associated with this filing provides key information on the trial's progress and its significance for the CoStarr stent. Investors should note that the success and findings of the COSTAR II trial are crucial for the future market acceptance and commercialization of the CoStarr stent. This report indicates Johnson & Johnson's ongoing commitment to advancing its cardiovascular product pipeline, with a particular focus on drug-eluting stent technology. Further details are available in the referenced press release (Exhibit 99.1).

Key Highlights

  • 1Johnson & Johnson's subsidiary, Conor Medsystems, LLC, issued a press release on May 7, 2007.
  • 2The press release discusses the COSTAR II clinical trial.
  • 3COSTAR II is a pivotal study for the CoStarr cobalt chromium paclitaxel-eluting coronary stent.
  • 4The CoStarr stent is designed to treat restenosis (re-narrowing of arteries).
  • 5This filing is made pursuant to Item 8.01 (Other Events) of Form 8-K.
  • 6The press release is incorporated by reference as Exhibit 99.1 to this report.

Frequently Asked Questions

The COSTAR II trial is a pivotal study, meaning its results are critical for determining the potential regulatory approval and market success of the CoStarr cobalt chromium paclitaxel-eluting coronary stent. Positive outcomes could lead to broader adoption of this new stent technology.

A paclitaxel-eluting coronary stent is a small, mesh-like tube that is expanded within a blocked coronary artery to reopen it. It is coated with paclitaxel, a drug that is slowly released to help prevent the artery from re-narrowing (restenosis) after the stent is implanted.

More detailed information about the COSTAR II trial is available in the press release dated May 7, 2007, which is included as Exhibit 99.1 with this 8-K filing.

Yes, Conor Medsystems, LLC is a wholly-owned subsidiary of Johnson & Johnson, meaning Johnson & Johnson owns all of its stock and has control over its operations.